HRP20130408T1 - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents
Disubstituted phthalazine hedgehog pathway antagonistsInfo
- Publication number
- HRP20130408T1 HRP20130408T1 HRP20130408AT HRP20130408T HRP20130408T1 HR P20130408 T1 HRP20130408 T1 HR P20130408T1 HR P20130408A T HRP20130408A T HR P20130408AT HR P20130408 T HRP20130408 T HR P20130408T HR P20130408 T1 HRP20130408 T1 HR P20130408T1
- Authority
- HR
- Croatia
- Prior art keywords
- hedgehog pathway
- pathway antagonists
- disubstituted phthalazine
- phthalazine hedgehog
- disubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 | |
| PCT/US2010/038568 WO2010147917A1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130408T1 true HRP20130408T1 (en) | 2013-06-30 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130408AT HRP20130408T1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
Country Status (35)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5442717B2 (ja) * | 2008-04-29 | 2014-03-12 | イーライ リリー アンド カンパニー | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
| CA2742539C (en) * | 2008-11-03 | 2014-05-06 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| EP2358703B1 (en) * | 2008-11-17 | 2013-12-25 | Eli Lilly and Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| DK2358698T3 (da) | 2008-11-17 | 2012-10-08 | Lilly Co Eli | Tetrasubstitueret pyridazin som hedgehog-pathway antagonister |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| EP2688565A1 (en) | 2011-03-23 | 2014-01-29 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| US9814703B2 (en) | 2013-11-14 | 2017-11-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of BMP signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| JP6796638B2 (ja) | 2015-06-04 | 2020-12-09 | ペレファーム, インク.Pellepharm, Inc. | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 |
| CA2987067A1 (en) * | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) * | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| EP3624798A1 (en) | 2017-05-18 | 2020-03-25 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| CA3184767A1 (en) | 2020-06-26 | 2021-12-30 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| JP2023546536A (ja) * | 2020-10-13 | 2023-11-02 | エンデバー バイオメディシンズ， インコーポレイテッド | 線維症を処置する方法 |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (enExample) | 1977-06-03 | 1981-03-07 | Pfizer | |
| AU717744B2 (en) | 1996-01-15 | 2000-03-30 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| AU768130B2 (en) | 1998-04-09 | 2003-12-04 | Johns Hopkins University School Of Medicine, The | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| ATE283700T1 (de) | 1999-06-08 | 2004-12-15 | Lorantis Ltd | Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges |
| AU2002327390B2 (en) * | 2001-07-27 | 2008-06-26 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| US7655674B2 (en) * | 2002-04-22 | 2010-02-02 | The Johns Hopkins University | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| WO2006004589A2 (en) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| AU2005282722C1 (en) | 2004-09-02 | 2011-08-18 | Curis, Inc. | Pyridyl inhibitors of hedgehog signalling |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| KR101473504B1 (ko) * | 2007-03-15 | 2014-12-16 | 노파르티스 아게 | 유기 화합물 및 그의 용도 |
| CA2690378A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| EP2188283B1 (en) | 2007-09-07 | 2012-08-15 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| WO2009074300A2 (en) * | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| JP5442717B2 (ja) | 2008-04-29 | 2014-03-12 | イーライ リリー アンド カンパニー | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| ES2433469T3 (es) * | 2008-08-04 | 2013-12-11 | Amgen Inc. | Moduladores de la aurora cinasa y métodos de uso |
| CA2742539C (en) | 2008-11-03 | 2014-05-06 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| DK2358698T3 (da) | 2008-11-17 | 2012-10-08 | Lilly Co Eli | Tetrasubstitueret pyridazin som hedgehog-pathway antagonister |
| EP2358703B1 (en) | 2008-11-17 | 2013-12-25 | Eli Lilly and Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216599A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| IL208211A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| ZA201102448B (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| ZA201400310B (en) | Solid dosage form | |
| GB0909680D0 (en) | Dosage form | |
| IL237392B (en) | Pharmaceutical combination | |
| IL220091A0 (en) | Pcsk9 antagonists | |
| GB2473319B (en) | Removable hydraulic-set packer | |
| AP3250A (en) | Tablets for combination therapy | |
| ZA201304617B (en) | Orally disintegrating tablet | |
| EP2389068A4 (en) | HEMGE OF THE HEDGEHOG SIGNAL PATH | |
| ZA201304366B (en) | Orally disintegrating tablet | |
| ZA201200761B (en) | Tablet | |
| AU330360S (en) | Tablet | |
| PT2293795E (pt) | Combinação farmacêutica | |
| GB0920041D0 (en) | Tablet | |
| HK1153467A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| GB0900643D0 (en) | Dosage assembly | |
| AU330359S (en) | Tablet | |
| AU331949S (en) | Tablet | |
| GB0910772D0 (en) | Pharmaceutical | |
| GB0918829D0 (en) | Monitor |